AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse,…

Continue Reading

News Source: medicalxpress.com